GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Jagsonpal Pharmaceuticals Ltd (BOM:507789) » Definitions » Capex-to-Revenue

Jagsonpal Pharmaceuticals (BOM:507789) Capex-to-Revenue : 0.00 (As of Dec. 2024)


View and export this data going back to 1991. Start your Free Trial

What is Jagsonpal Pharmaceuticals Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Jagsonpal Pharmaceuticals's Capital Expenditure for the three months ended in Dec. 2024 was ₹0.00 Mil. Its Revenue for the three months ended in Dec. 2024 was ₹740.25 Mil.

Hence, Jagsonpal Pharmaceuticals's Capex-to-Revenue for the three months ended in Dec. 2024 was 0.00.


Jagsonpal Pharmaceuticals Capex-to-Revenue Historical Data

The historical data trend for Jagsonpal Pharmaceuticals's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jagsonpal Pharmaceuticals Capex-to-Revenue Chart

Jagsonpal Pharmaceuticals Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 - 0.01 - -

Jagsonpal Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Jagsonpal Pharmaceuticals's Capex-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Jagsonpal Pharmaceuticals's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jagsonpal Pharmaceuticals's Capex-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Jagsonpal Pharmaceuticals's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Jagsonpal Pharmaceuticals's Capex-to-Revenue falls into.


;
;

Jagsonpal Pharmaceuticals Capex-to-Revenue Calculation

Jagsonpal Pharmaceuticals's Capex-to-Revenue for the fiscal year that ended in Mar. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-2.48) / 2087.02
=0.00

Jagsonpal Pharmaceuticals's Capex-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 740.25
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Jagsonpal Pharmaceuticals  (BOM:507789) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Jagsonpal Pharmaceuticals Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Jagsonpal Pharmaceuticals's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Jagsonpal Pharmaceuticals Business Description

Traded in Other Exchanges
Address
3rd Floor, Phase – IV, Udyog Vihar, Plot No. 412-415, Nimai Tower, Gurugram, HR, IND, 122015
Jagsonpal Pharmaceuticals Ltd is a pharmaceutical company. It develops and manufactures active pharmaceutical ingredients and formulations like Capsule and Tablet. The company operates in the Gynaecology, Orthopaedics, Dermatology and Paediatric segments. Its brands comprise Lycored, Maintane, Metadec, Metabol, Doxypal DR, and others.

Jagsonpal Pharmaceuticals Headlines

No Headlines